ETX-0282

Class: Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO])

Details of activity:	DBOs bind reversibly to the beta-lactamase in the active site, inhibits class A, C, D and weakly inhibits penicillin binding protein 2 in Enterobacteriaceae
Combined with other compounds:	Yes
Description:	Synthetic compound. Isopropyl ester prodrug of ETX-1317. In clinical development in fixed combination with cefpodoxime proxetil. Oral application
Institute where first reported:	Entasis Therapeutics, Innoviva
Year first mentioned:	2019
Highest developmental phase:	Phase 1 (as of 2022)
Development status:	Active (as of 2022)

Chemical structure(s):
Canonical SMILES:	CC(C)OC(=O)[C@@H](F)ON1[C@H]2CN([C@H](C=C2C)C(=O)N)C1=O
Isomeric SMILES:	CC1=C[C@@H](N2C[C@@H]1N(C2=O)O[C@@H](C(=O)OC(C)C)F)C(=O)N
InChI:	InChI=1S/C13H18FN3O5/c1-6(2)21-12(19)10(14)22-17-9-5-16(13(17)20)8(11(15)18)4-7(9)3/h4,6,8-10H,5H2,1-3H3,(H2,15,18)/t8-,9+,10+/m1/s1
InChI Key:	OMNVFPBGXYKTDB-UTLUCORTSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/146170992

External links:
Guide to Pharmacology:	ETX1317
Main Source:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927146/
Citations:	https://pubmed.ncbi.nlm.nih.gov/33291867/ https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00020